Study to Assess the Pharmacokinetics of CT1812 in Older Healthy Volunteers

Inclusion Criteria: * Men and Women 50-80 years of age, inclusively * In good health as determined by the Investigator with no clinically significant abnormalities * Weight between 50.0 and 100.0 kg, inclusive at Screening * No suicidal ideation * No active depression * Living independently at home or in a community setting * Able to swallow CT1812 capsule or capsules * Non-smoker with no history of using tobacco or any nicotine-containing products * Subjects with negative serology for HIV, Hepatitis B, and C * Negative results for drugs of abuse, cotinine, and alcohol * Negative test results for COVID-19 * Willing to comply with Clinical Pharmacology Unit's COVID-19 policies Exclusion Criteria: * Any chronic medical condition which, in the opinion of the investigator, might pose a safety risk to the subject or interfere with study interpretation * Subject with active or recent infection requiring antibiotic therapy * Medical history of vasculitis or any autoimmune disease * Any recent hospitalization * Subjects living in a continuous care nursing facility * Any contraindication to a lumbar puncture * Subjects with self-reported history of major depression * History of diabetes * Intake of drugs or substances potentially involved in clinically significant induction or inhibition of CYP3A4 or P-gp mediated drug interactions with CT1812 * Intake of investigational drug prior to study drug administration on Day 1 * Participation in an investigational device study prior to study drug administration on Day 1 * Grapefruit, grapefruit juice, and Seville oranges/juice must be avoided within 14 days prior to dosing and throughout the course of the study * Suspected or known drug or alcohol abuse, * Excessive consumption of coffee, tea, cola, or other caffeinated beverages * Loss or donation of blood; nation of bone marrow or peripheral stem cells; or donation of plasma * Venous access considered inadequate; history or evidence of adverse symptoms associated with phlebotomy or blood donation * Suspected or known allergy to any component of the study treatments * Employee or family member of the Investigator, study site personnel, or Sponsor * A subject with any condition that, in the opinion of the Investigator, makes the subject unsuitable for study participation will be excluded